Credit Suisse Upgrades Clovis Oncology (CLVS) to Outperform on Takeout Potential
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Clovis Oncology (CLVS) takeover chatter may be overdone - TheStreet
September 23, 2016 10:04 AM EDTClovis Oncology (NASDAQ: CLVS) takeover chatter may be overdone - TheStreet
... MoreClovis Oncology (CLVS) Gains Again Amid Continued Takeover Chatter
September 22, 2016 10:42 AM EDTRumored takeover target Clovis Oncology (NASDAQ: CLVS) is gaining again. Shares are up 5.5%. Shares are up 189% over the last 3 months, up 109% over the last month and up 23% over the last 5 days.
... MoreClovis Oncology (CLVS) PT Raised to $45 at Stifel Amid De-Risking Events
September 21, 2016 7:30 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and raised his price target on Clovis Oncology (NASDAQ: CLVS) to $45.00 (from $30.00), saying recent events de-risk the stock.
Shrader commented, "A series of events in the last few weeks have seemed to de-risk the Clovis story including the acceptance of the rucaparib NDA, the lack of an ODAC panel and a final update for olaparib that suggests that PARP inhibitors may never show an OS benefit in the ovarian cancer (OC) maintenance setting (not... More
Clovis Oncology (CLVS) Adds to Intra-Day Gains on Rampant M&A Chatter
September 20, 2016 4:56 PM EDTClovis Oncology (NASDAQ: CLVS) adds to intra-day rumor-fueled gains after-hours. Shares are up 6% after-hours after gaining 12.7% intra-day on increased takeover chatter.
... MoreUPDATE: Clovis Oncology (CLVS) Shares Spike to Session Highs Amid Chatter (GILD) (LLY)
September 20, 2016 2:58 PM EDT(Updated - September 20, 2016 3:00 PM EDT)
Clovis Oncology (Nasdaq: CLVS) shares spike to session highs.
UPDATE - Market chatter recently speculated that Clovis has been eyed as a potential target for Gilead Sciences (NASDAQ:... More
